Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Trading Cabana -- Ignore unavailable to you. Want to Upgrade?

To: RockyBalboa who wrote (5465)	5/13/2009 12:09:21 PM
From: RockyBalboa	Respond to of 6370

UPDATE 1-Genta sees running out of funds in June May 12 (Reuters) - Biopharmaceutical company Genta Inc said it expects to run out of funds in June and could be required to reduce its workforce or file for bankruptcy, among other options, if it is unable to raise money. In a statement, the company said it does not have any additional financing in place. At March 31, it had cash and cash equivalents totaling about $600,000. In April, Genta agreed to a private placement of up to $12 million of senior secured convertible notes, and the agreement requires the company to effect a reverse stock split of its common stock within 105 days of April 2, the company said. The notes and warrants are convertible into about 3.9 billion shares, but the company currently has about 3.4 billion shares outstanding, Genta said. Genta, which had cut jobs in April and May to reduce expenses, said it has recommended that its stockholders authorize the company's board to effect a reverse split in any ratio from 1-for-2 to 1-for-100. Genta, whose rivals include Amgen Inc and Gilead Sciences , also reported a first-quarter loss of $11.1 million, or 1 cent per share, compared with a net loss of $9.7 million, or 29 cents per share, a year ago. (Reporting by Santosh Nadgir in Bangalore; Editing by Deepak Kannan) ((santosh.nadgir@thomsonreuters.com; within U.S +1 646 223 8780; Outside U.S +91 080 4135 5800; Reuters messaging: santosh.nadgir.reuters.com@reuters.net)) Keywords: GENTA/